Projects

Unravelling transcriptomic differences in chronic myeloid leukemia responder and non-responder (with and without mutations) to understand the biology of therapy resistance

Project Description

Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation. Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.

Project Duration

2024 - 2027

Project Lead

Dr Sweta Srivastava

Authors

Dr. Sweta, Ms. Sharon E

Project Status

ongoing

Project Type

PI